The cybersecurity firm Varonis is navigating a difficult period, with its recent quarterly report triggering a significant decline in its stock price. The company’s strategic shift to cloud-based services, intended to be a managed transition, has instead revealed substantial operational hurdles.
Financial Performance and Contract Setbacks
For the latest quarter, Varonis reported revenue of $161.6 million, a figure that fell short of market expectations. A deeper look into the revenue composition highlights the core issue. Although revenue from Software-as-a-Service (SaaS) climbed to $125.8 million, accounting for 76% of total business, the legacy on-premise segment contracted sharply. Compounding the problem, U.S. federal agencies, which represent 5% of the company’s customer base, did not renew their contracts as anticipated.
This combination of factors resulted in a GAAP operating loss of $35.9 million, a stark contrast to the company’s profitability goals and forcing management to implement immediate corrective actions.
Strategic Shifts and Cost-Cutting Measures
In response to the disappointing results, Varonis announced a restructuring plan that includes reducing its workforce by approximately 5%, affecting about 120 employees. The company also issued a substantially lowered financial outlook for 2025, now forecasting revenue between $615 million and $621 million. This revised guidance implies an annual growth rate of just 12% to 13%.
Should investors sell immediately? Or is it worth buying Varonis?
On a more positive note, the company’s board authorized a new $150 million share repurchase program. This initiative is designed to demonstrate confidence in the company’s long-term value and help stabilize the equity price.
Mixed Reactions from Market Analysts
Financial analysts have expressed divergent views on the company’s prospects. Wedbush maintained its “Outperform” rating and even raised its 2025 profit estimate, reaffirming a $65 price target. Similarly, Cantor Fitzgerald continues to rate the stock as “Overweight” with a $60 target.
Overall, the analyst consensus remains cautiously optimistic. Among the covering firms, 16 recommend buying the shares, four suggest holding, and two advise selling. The average price target among analysts stands at $60.74, which is significantly higher than the current trading level. The critical uncertainty is whether this analyst confidence can help restore investor faith.
The coming quarters will be decisive in determining if Varonis can successfully execute its business model transformation or if the recent downturn marks the beginning of a more prolonged challenge.
Ad
Varonis Stock: Buy or Sell?! New Varonis Analysis from November 4 delivers the answer:
The latest Varonis figures speak for themselves: Urgent action needed for Varonis investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 4.
Varonis: Buy or sell? Read more here...
			









